Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
William W. Busse(University of Wisconsin–Madison), Christine A. Sorkness(University of Wisconsin–Madison), Suzanne Steinbach(Boston University), Stanley J. Szefler(Children's Hospital Colorado), Katherine M. Thompson(Zetec (United States)), Meyer Kattan(Icahn School of Medicine at Mount Sinai), James F. Chmiel(Riley Hospital for Children), Jacqueline A. Pongracic(Lurie Children's Hospital), Rebecca S. Gruchalla(The University of Texas Southwestern Medical Center), Alkis Togias(National Institute of Allergy and Infectious Diseases), Stephen J. Teach(Children's National), Peter J. Gergen(National Institutes of Health), Wayne J. Morgan(University of Arizona), Andrew H. Liu(Children's Hospital Colorado), Agustin Calatroni(Johns Hopkins University), Herman Mitchell(Rho (United States)), James E. Gern(University of Wisconsin–Madison)
Cited by 870
Related Papers
Asthma and Wheezing in the First Six Years of Life
|New England Journal of Medicine|1995|3.8k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
|Journal of Allergy and Clinical Immunology|2006|2.3k
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
|The Lancet|1999|1.6k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k